Interim analysis of the phase II AVETUXIRI trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC). This is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback